/PRNewswire/ A study published in this month s issue of the National Kidney Foundation American Journal of Kidney Diseases (AJKD) provides new insights into.
The findings provide support for potentially using aprocitentan in patients with BP that remains elevated despite treatment with three established antihypertensive drug classes and with stage 3 CKD.